Análisis de la utilización clínica y consumo de ertapenem

• Autores: Yolanda Arco Prados, Ernesto Sánchez Gómez, Esmeralda Rodríguez Molins, María Teresa Garrido Martínez
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 14, Nº. 6, 2012, págs. 424-431
• Idioma: español
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objectives: To describe the clinical use of ertapenem in a specialty hospital, assess the evolution of its consumption, and quantify the extra cost of using ertapenem versus its non-inferior alternatives that are not subject to patent. Method: Retrospective, descriptive and observational study conducted in a specialty hospital. We selected those patients who received at least one dose of ertapenem. The information was obtained from a review of clinical records. Consumption of ertapenem and its alternatives in years 2004-2011 was determined using the pharmacy department's management software, and the drugs were compared using the daily defined dose/100 stays/day. Invoiced prices were used to determine the monetary costs. Results: 90 patients were analyzed. The prescribing departments were: General Surgery, Internal Medicine, Vascular Surgery, and others, being the percentage of use of ertapenem in them 62.2%, 26.7%, 6.7% and 4.4%, respectively. In 97.7% of all the prescribed treatments there was an equally effective and lower cost alternative in economic terms, mainly: piperacillin/tazobactam or amoxicillin/clavulanic acid. In the period 2006-2011, the use of those options would have decreased consumption cost by 157,213.84 in case of piperacillin/tazobactam and 215,964.95 in case of amoxicillin/clavulanic acid. The use of ertapenem has not only increased, but also exceeded that of piperacillin/tazobactam during 2007 and 2008 in General Surgery. Conclusions: Instead of ertapenem, we could use other alternatives in most clinical situations that require it, and furthermore, these non-inferior generic alternatives would generate significant economic savings